Fingolimod (hydrochloride)

Fingolimod (hydrochloride)

• Product Name Alternative: FTY720
• CAS Number: 162359-56-0
• UNSPSC Description: Fingolimod (FTY720) hydrochloride is a sphingosine 1-phosphate (S1P) antagonist with IC50 of 0.033 nM in K562 and NK cells. Fingolimod hydrochloride is also a pak1 activator and immunosuppressant[1][2][3][4].
• Target Antigen: LPL Receptor; PAK
• Type: Reference compound
• Related Pathways: Cell Cycle/DNA Damage;Cytoskeleton;GPCR/G Protein
• Field of Research: Inflammation/Immunology; Cancer
• Assay Protocol: https://www.medchemexpress.com/Fingolimod-hydrochloride.html
• Purity: 99.95
• Solubility: DMSO : ≥ 100 mg/mL|Ethanol : 100 mg/mL (ultrasonic)|H2O : 50 mg/mL (ultrasonic)
• Smiles: OCC(N)(CO)CCC1=CC=C(C=C1)CCCCCCCC.[H]Cl
• Molecular Weight: 343.93
• References & Citations: [1]Rolin J, et al. FTY720 and SEW2871 reverse the inhibitory effect of S1P on natural killer cell mediated lysis of K562 tumor cells and dendritic cells but not on cytokine release. Cancer Immunol Immunother. 2010, 59(4), 575-586.|[2]Coldewey SM, et al. Elevation of serum sphingosine-1-phosphate attenuates impaired cardiac function in experimental sepsis. Sci Rep. 2016 Jun 9;6:27594.|[3]Cipriani R, et al. FTY720 attenuates excitotoxicity and neuroinflammation. J Neuroinflammation. 2015 May 8;12:86.|[4]Arielle M Bryan, et al. Sphingosine-1-phosphate receptors and innate immunity. Cell Microbiol. 2018 May;20(5):e12836.Adv Sci (Weinh). 2024 Jul 23:e2404080.|Autophagy. 2024 Jul 2.|Bioorg Chem. 2024 Apr 29:147:107412.|Breast Cancer Res. 2017 Aug 4;19(1):90. |Cancer Lett. 2018 Aug 16;436:75-86. |Cell Rep Med. 2024 Jun 18;5(6):101590.|Cell Res. 2022 Feb 1.|Curr Eye Res. 2024 Apr 5:1-10.|Eur J Pharmacol. 2022 Sep 12;175271.|FASEB J. 2024 Jan 31;38(2):e23417.|Haematologica. 2020 Mar;105(3):674-686.|Int Immunopharmacol. 2021 Apr 26;96:107511.|Int Immunopharmacol. 2024 Oct 31;143(Pt 3):113526.|J Immunol Sci. March 31, 2022.|J Immunol. 2024 Oct 14:ji2400088.|Life Sci. 2019 Jan 15;217:243-250.|Nat Commun. 2022 Jan 10;13(1):182.|Nat Commun. 2024 Jun 13;15(1):5056.|Nat Commun. 2024 May 31;15(1):4665.|Nat Commun. 2024 Sep 8;15(1):7850.|Patent. US20210393524A1.|PLoS Negl Trop Dis. 2019 Aug 20;13(8):e0007681. |Reprod Biomed Online. 2023 Jul 22, 103304.|Research Square Preprint. 2023 Dec 1.|Theranostics. 2021 Jan 1;11(1):117-131.|Vet Microbiol. 2021, 109177.|Am J Physiol Cell Physiol. 2023 Oct 2.|Biomed Chromatogr. 2024 Jun 26:e5947.|Commun Biol. 2021 Mar 25;4(1):399.|Front Endocrinol (Lausanne). 2018 Mar 22;9:120. |Front Pharmacol. 2018 Oct 31;9:1237. |Helicobacter. 2019 Oct;24(5):e12652.|Immunity. 2024 Feb 13;57(2):364-378.e9.|J Gastroenterol Hepatol. 2018 Jan 15. |J Integr Neurosci. 2024 Aug 12;23(8):142.|J Mol Cell Cardiol. 2021 Nov 10;S0022-2828(21)00210-8.|Mol Neurobiol. 2023 Oct 11.|Res Sq. 2024 Oct 18.|Research Square Preprint. 2023 Sep 6.|Research Square Preprint. 2024 Apr 23.|RSC Adv. 2024 Jul 12;14(30):22044-22055.|Wound Repair Regen. 2023 May 2.
• Shipping Conditions: Room Temperature
• Storage Conditions: 4°C (Powder, sealed storage, away from moisture)
• Clinical Information: Launched